Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosome-sonotherapy for dystrophic muscle repair in Duchenne muscular dystrophy
IRCT20250111064352N1Phase 2Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of endothelial progenitor cell-derived exosomes in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Golestan University of Medical Sciences. Primary endpoints: Muscle thickness, Muscle compressibility and 2 more. Started Jan 2025; status: completed.
02
Drugs
endothelial progenitor cell-derived exosomes
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on IRCT20250111064352N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250111064352N1.